臨床泌尿器科70巻9号

2016年08月発行

特集 泌尿器科医のための放射線治療学講座─基礎から徹底的に理解する

〈泌尿器科臨床への応用〉

放射線増感

著者： 芝本雄太¹

所属機関： ¹名古屋市立大学大学院医学研究科放射線医学分野

ページ範囲：P.680 - P.684

文献概要

▶ポイント

・放射線増感の代表は低酸素細胞増感剤であるが，通常分割照射との併用効果は弱く，定位照射などの1回大線量照射との併用が期待される．

・ほかには，低酸素特異的抗腫瘍剤，過酸化水素注入療法，温熱療法，低薬量抗がん剤などがある．

・泌尿器科領域では，膀胱癌に対して低濃度シスプラチンの同時併用が行われるが，大きな腫瘍に対する過酸化水素注入も今後期待できる．

参考文献

1） Shibamoto Y, Nishimoto S, Mi F, et al : Evaluation of various types of new hypoxic cell sensitizers using the EMT6 single cell-spheroid-solid tumour system. Int J Radiat Biol Relat Stud Phys Chem Med 52 : 347─357, 1987

2） Tsutsui K, Komuro C, Ono K, et al : Chemosensitization by buthionine sulfoximine in vivo. Int J Radiat Oncol Biol Phys 12 : 1183─1186, 1986

3） Shibamoto Y, Sugie C, Ito M, et al : The Japanese experiences with hypoxia-targeting pharmacoradiotherapy : from hypoxic cell sensitisers to radiation-activated prodrugs. Expert Opin Pharmacother 5 : 2459─2467, 2004

4） Shibamoto Y, Yukawa Y, Tsutsui K, et al : Variation in the hypoxic fraction among mouse tumors of different types, sizes and sites. Jpn J Cancer Res 77 : 908─915, 1986

5） Adams GE, Hasan NM and Joiner MC : The Llaas Breur Lecture. Radiation, hypoxia and genetic stimulation : implications for future therapies. Radiother Oncol 44 : 101─109, 1997

6） Shibamoto Y, Nishimoto S, Shimokawa K, et al : Characteristics of fluorinated nitroazoles as hypoxic cell radiosensitizers. Int J Radiat Oncol Biol Phys 16 : 1045─1048, 1989

7） Shibamoto Y, Kubota T, Kishii K, et al : Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole. Radiother Oncol 56 : 265─270, 2000

8） Shibamoto Y, Sakano K, Kimura R, et al : Radiosensitization in vitro and in vivo by 3-nitrotriazoles. Int J Radiat Oncol Biol Phys 12 : 1063─1066, 1986

9） Shibamoto Y, Ohshio G, Hosotani R, et al : A phase I/II study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy. Br J Cancer 76 : 1474─1479, 1997

10） Karasawa K, Sunamura M, Okamoto A, et al : Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer : long-term results of a placebo-controlled randomised study. Radiother Oncol 87 : 326─330, 2008

11） Sealy R : Hyperbaric oxygen in the radiation treatment of head and neck cancers. Radiother Oncol 20 : 75─79, 1991

12） Ogawa Y, Kubota K, Aoyama N, et al : Non-surgical breast-conserving treatment （KORTUC-BCT） using a new radiosensitization method （KORTUC II） for patients with stage I or II breast caner. Cancers 7 : 2277─2289, 2015

13） Shibamoto Y, Zhou L, Hatta H, et al : A novel class of antitumor prodrug, 1- （2'-oxopropyl） -5-fluorouracil （OFU001） that releases 5-fluorouracil upon hypoxic irradiation. Jpn J Cancer Res 91 : 433─438, 2000

14） Shibamoto Y, Tachi Y, Tanabe K, et al : In vitro and in vivo evaluation of novel antitumor prodrugs of 5-fluoro-2'-deoxyuridine activated by hypoxic irradiation. Int J Radiat Oncol Biol Phys 58 : 397─402, 2004

15） Shibamoto Y, Nishimura Y and Abe M : Intraoperative radiotherapy and hyperthermia for unresectable pancreatic cancer. Hepato gastroenterol 43 : 326─332, 1996

16） Reddy SB and Williamson SK : Tirapazamine : a novel agent targeting hypoxic tumor cells. Expert Opin Investig Drugs 18 : 77─87, 2009

17） Jeremic B, Shibamoto Y, Acimovic L, et al : Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer : a randomized study. J Clin Oncol 14 : 1065─1070, 1996

18） Jeremic B, Shibamoto Y, Stanisavljevic B, et al : Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck : a prospective randomized trial. Radiother Oncol 43 : 29─37, 1997

19） Jeremic B, Shibamoto Y, Acimovic L, et al : Accelerated hyperfractionated radiation therapy and concurrent 5- fluorouracil/cisplatin chemotherapy for locoregional squamous cell carcinoma of the thoracic esophagus : a phase II study. Int J Radiat Oncol Biol Phys 40 : 1061─1066, 1998

20） Mitin T, Hunt D, Shipley WU, et al : Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer （RTOG0233） : a randomized multicentre phase 2 trial. Lancet Oncol 14 : 863─872, 2013